436 related articles for article (PubMed ID: 26996405)
1. Oral Dimethyl Fumarate in Children With Multiple Sclerosis: A Dual-Center Study.
Makhani N; Schreiner T
Pediatr Neurol; 2016 Apr; 57():101-4. PubMed ID: 26996405
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study.
Miclea A; Leussink VI; Hartung HP; Gold R; Hoepner R
J Neurol; 2016 Aug; 263(8):1626-32. PubMed ID: 27260297
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis.
Venci JV; Gandhi MA
Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R; Arnold DL; Bar-Or A; Hutchinson M; Kappos L; Havrdova E; MacManus DG; Yousry TA; Pozzilli C; Selmaj K; Sweetser MT; Zhang R; Yang M; Potts J; Novas M; Miller DH; Kurukulasuriya NC; Fox RJ; Phillips TJ
Mult Scler; 2017 Feb; 23(2):253-265. PubMed ID: 27207449
[TBL] [Abstract][Full Text] [Related]
7. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study.
Pilo de la Fuente B; Sabín J; Galán V; Thuissard I; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Lozano-Ros A; García-Domínguez JM; Borrego L; Ayuso L; Castro A; Sánchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodríguez-García E; Andreu-Vázquez C; Blasco R; García-Merino JA; Aladro Y;
CNS Drugs; 2020 Dec; 34(12):1275-1286. PubMed ID: 33226562
[TBL] [Abstract][Full Text] [Related]
8. Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review.
Suneetha A; Raja Rajeswari K
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1019():15-20. PubMed ID: 26899449
[TBL] [Abstract][Full Text] [Related]
9. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK
Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Deeks ED
Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
12. [Extending therapeutic possibilities in relapsing-remitting multiple sclerosis: dimethyl fumarate].
Matolcsi J; Rózsa C
Ideggyogy Sz; 2015 Jan; 68(1-2):7-14. PubMed ID: 25842911
[TBL] [Abstract][Full Text] [Related]
13. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis.
Saijo N; Abe Y; Oikawa Y; Okubo Y; Endo W; Numata-Uematsu Y; Takahashi T; Uematsu M
Brain Dev; 2022 May; 44(5):353-356. PubMed ID: 35058083
[TBL] [Abstract][Full Text] [Related]
15. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects.
Linker RA; Gold R
Curr Neurol Neurosci Rep; 2013 Nov; 13(11):394. PubMed ID: 24061646
[TBL] [Abstract][Full Text] [Related]
16. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
Eckstein C; Bhatti MT
Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
[TBL] [Abstract][Full Text] [Related]
17. Erythema nodosum in a patient with multiple sclerosis on dimethyl fumarate.
Algahtani H; Shirah B; Marghalani S; Algarni A
Mult Scler Relat Disord; 2019 Feb; 28():155-158. PubMed ID: 30597324
[TBL] [Abstract][Full Text] [Related]
18. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
[TBL] [Abstract][Full Text] [Related]
19. Transient hair loss during treatment with dimethyl-fumarate for multiple sclerosis.
Losavio FA; Lucchini M; De Fino C; Mirabella M; Nociti V
Mult Scler Relat Disord; 2016 May; 7():68-9. PubMed ID: 27237761
[TBL] [Abstract][Full Text] [Related]
20. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]